Covid-19–related hospitalization or death from any cause was less frequent in the remdesivir group
Remdesivir: 0.7% (2 patients)
Placebo: 5.3% (15 patients)
Hazard ratio (HR) 0.13 (95% CI, 0.03 to 0.59); P=0.008
Patients in the remdesivir group were less likely to need medical treatment by day 28
HR 0.19 (95% CI, 0.07 to 0.56)
No patients had died by day 28
Most common in ≥5% in both groups
Nausea | Headache | Cough
Adverse events related to the trial regimen
Placebo group: 8.8%
Overall, fewer patients in the remdesivir group had serious adverse events
Non-hospitalized patients with COVID-19 and risk factors for disease progression who received a 3-day course of remdesivir were 87% less likely to require hospitalization or die compared to patients who received placebo
Remdesivir had an acceptable safety profile in this population with incidence of adverse events similar to placebo
The authors state
In the campaign toward ending the Covid-19 pandemic, these data add yet another option to the armamentarium for the treatment of vulnerable patients who are at high risk for progression to severe Covid-19
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan